199 related articles for article (PubMed ID: 38672562)
1. Investigating the Role of
Lautert-Dutra W; Melo CM; Chaves LP; Sousa FC; Crozier C; Dion D; Avante FS; Saggioro FP; Dos Reis RB; Archangelo LF; Bayani J; Squire JA
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672562
[TBL] [Abstract][Full Text] [Related]
2. Integrating single-cell and bulk RNA sequencing data unveils antigen presentation and process-related CAFS and establishes a predictive signature in prostate cancer.
Wang W; Li T; Xie Z; Zhao J; Zhang Y; Ruan Y; Han B
J Transl Med; 2024 Jan; 22(1):57. PubMed ID: 38221616
[TBL] [Abstract][Full Text] [Related]
3. Establishment of an age- and tumor microenvironment-related gene signature for survival prediction in prostate cancer.
Chen L; Zhang M; Zhou J; Zhang L; Liang C
Cancer Med; 2022 Nov; 11(22):4374-4388. PubMed ID: 35535438
[TBL] [Abstract][Full Text] [Related]
4. Roles of m5C RNA Modification Patterns in Biochemical Recurrence and Tumor Microenvironment Characterization of Prostate Adenocarcinoma.
Xu Z; Chen S; Zhang Y; Liu R; Chen M
Front Immunol; 2022; 13():869759. PubMed ID: 35603206
[TBL] [Abstract][Full Text] [Related]
5. Loss of heterozygosity impacts MHC expression on the immune microenvironment in CDK12-mutated prostate cancer.
Lautert-Dutra W; M Melo C; Chaves LP; Crozier C; P Saggioro F; B Dos Reis R; Bayani J; Bonatto SL; Squire JA
Mol Cytogenet; 2024 May; 17(1):11. PubMed ID: 38704603
[TBL] [Abstract][Full Text] [Related]
6. Development and validation of novel inflammatory response-related gene signature to predict prostate cancer recurrence and response to immune checkpoint therapy.
Luo Y; Liu X; Lin J; Zhong W; Chen Q
Math Biosci Eng; 2022 Aug; 19(11):11345-11366. PubMed ID: 36124593
[TBL] [Abstract][Full Text] [Related]
7. Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer.
Wang C; Tang Y; Ma H; Wei S; Hu X; Zhao L; Wang G
Front Genet; 2022; 13():919389. PubMed ID: 35783281
[No Abstract] [Full Text] [Related]
8. The molecular feature of macrophages in tumor immune microenvironment of glioma patients.
Zhang H; Luo YB; Wu W; Zhang L; Wang Z; Dai Z; Feng S; Cao H; Cheng Q; Liu Z
Comput Struct Biotechnol J; 2021; 19():4603-4618. PubMed ID: 34471502
[TBL] [Abstract][Full Text] [Related]
9. A Ferroptosis-Related Gene Prognostic Index Associated With Biochemical Recurrence and Radiation Resistance for Patients With Prostate Cancer Undergoing Radical Radiotherapy.
Feng D; Shi X; Xiong Q; Zhang F; Li D; Wei W; Yang L
Front Cell Dev Biol; 2022; 10():803766. PubMed ID: 35223835
[No Abstract] [Full Text] [Related]
10. Identifies microtubule-binding protein
Wang W; Zhang J; Wang Y; Xu Y; Zhang S
Comput Struct Biotechnol J; 2022; 20():3322-3335. PubMed ID: 35832625
[TBL] [Abstract][Full Text] [Related]
11. Histone lysine methylation patterns in prostate cancer microenvironment infiltration: Integrated bioinformatic analysis and histological validation.
Quan Y; Zhang X; Wang M; Ping H
Front Oncol; 2022; 12():981226. PubMed ID: 36237332
[TBL] [Abstract][Full Text] [Related]
12. CD47 is a direct target of SNAI1 and ZEB1 and its blockade activates the phagocytosis of breast cancer cells undergoing EMT.
Noman MZ; Van Moer K; Marani V; Gemmill RM; Tranchevent LC; Azuaje F; Muller A; Chouaib S; Thiery JP; Berchem G; Janji B
Oncoimmunology; 2018; 7(4):e1345415. PubMed ID: 29632713
[TBL] [Abstract][Full Text] [Related]
13. Identification of tumor-agnostic biomarkers for predicting prostate cancer progression and biochemical recurrence.
Lautert-Dutra W; Melo CM; Chaves LP; Souza FC; Crozier C; Sundby AE; Woroszchuk E; Saggioro FP; Avante FS; Dos Reis RB; Squire JA; Bayani J
Front Oncol; 2023; 13():1280943. PubMed ID: 37965470
[TBL] [Abstract][Full Text] [Related]
14. High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot.
Keam SP; Halse H; Nguyen T; Wang M; Van Kooten Losio N; Mitchell C; Caramia F; Byrne DJ; Haupt S; Ryland G; Darcy PK; Sandhu S; Blombery P; Haupt Y; Williams SG; Neeson PJ
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581061
[TBL] [Abstract][Full Text] [Related]
15. LTBP2 inhibits prostate cancer progression and metastasis via the PI3K/AKT signaling pathway.
Zhang X; Tian C; Cheng J; Mao W; Li M; Chen M
Exp Ther Med; 2022 Sep; 24(3):563. PubMed ID: 36034756
[TBL] [Abstract][Full Text] [Related]
16. Identification of Prostate Cancer Risk Genetics Biomarkers Based on Intergraded Bioinformatics Analysis.
Liang X; Wang Y; Pei L; Tan X; Dong C
Front Surg; 2022; 9():856446. PubMed ID: 35372462
[TBL] [Abstract][Full Text] [Related]
17. Identification and validation of cancer-associated fibroblast-related subtypes and the prognosis model of biochemical recurrence in prostate cancer based on single-cell and bulk RNA sequencing.
Li T; Zhou Z; Xie Z; Fan X; Zhang Y; Zhang Y; Song X; Ruan Y
J Cancer Res Clin Oncol; 2023 Oct; 149(13):11379-11395. PubMed ID: 37369799
[TBL] [Abstract][Full Text] [Related]
18. Copy number gain of ZEB1 mediates a double-negative feedback loop with miR-33a-5p that regulates EMT and bone metastasis of prostate cancer dependent on TGF-β signaling.
Dai Y; Wu Z; Lang C; Zhang X; He S; Yang Q; Guo W; Lai Y; Du H; Peng X; Ren D
Theranostics; 2019; 9(21):6063-6079. PubMed ID: 31534537
[No Abstract] [Full Text] [Related]
19. Identification of Key Genes Associated with Tumor Microenvironment Infiltration and Survival in Gastric Adenocarcinoma via Bioinformatics Analysis.
Konstantis G; Tsaousi G; Pourzitaki C; Kasper-Virchow S; Zaun G; Kitsikidou E; Passenberg M; Tseriotis VS; Willuweit K; Schmidt HH; Rashidi-Alavijeh J
Cancers (Basel); 2024 Mar; 16(7):. PubMed ID: 38610959
[TBL] [Abstract][Full Text] [Related]
20. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
Wang N; Zhu L; Wang L; Shen Z; Huang X
Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
